Guest Editorial ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations January 20, 2023Vol.49 No.03By Mikkael A. Sekeres
Guest Editorial Ending cancer as we know it—for everyone—begins with the numbers January 13, 2023Vol.49 No.02By William L. Dahut
FreeGuest Editorial A New Year’s greeting from Ukraine January 06, 2023Vol.49 No.01By Andriy Beznosenko
FreeGuest Editorial S2302 Pragmatica-Lung Trial: Reaching more representative groups of patients with exciting clinical trials December 21, 2022Vol.48 No.46By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
FreeGuest Editorial NCI’s Cancer Prevention-Interception Targeted Agent Discovery (CAP-IT) Program, a milestone in cancer prevention research December 21, 2022Vol.48 No.46By Margie Clapper
Guest Editorial PAMN: How cancer centers develop ways to communicate the value of research December 09, 2022Vol.48 No.44By Heidi Findlay
Guest Editorial A “new normal” for NCI-sponsored clinical trials is long overdue November 18, 2022Vol.48 No.42By Richard L. Schilsky
Guest Editorial Lung cancer screening: New guidelines, new challenges November 18, 2022Vol.48 No.42By David Balis
Guest Editorial AACR and ASCO release updated e-cigarette policy statement; FDA action should follow October 28, 2022Vol.48 No.39By Roy S. Herbst
FreeGuest Editorial Preventing the “Killing Twice Effect”: What we can do to support Ukrainian oncology professionals during the war October 21, 2022Vol.48 No.38By Nataliya Kovalchuk, Yuliia Lozko, Yuliia Severyn, Andriy Beznosenko, Ruslan Zelinsky, Nelya Melnitchouk, Viktor Iakovenko, Roman Kowalchuk and Natalka Suchowerska
